Current Position: Product Center
Anti-ITGB4 mIgG2a Antibody(13H10)
Cat. No.
GM-88290AB
Size
10μg
100μg
1mg
Quote
数据展示
产品简介
Related products
数据展示
GM-88290AB
On SDS-PAGE under reducing (R)/non-reducing(N-R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of this product is more than 95% verified by SEC-HPLC.
产品简介

Species Reactivity      Human

Clone                          13H10

Source/Isotype           Mouse IgG2a,Kappa

Application                 /

Specificity                   Detects ITGB4

Gene                            ITGB4

Other Names              CD104, GP150, JEB5A, JEB5B

Gene ID                       3691 (Human)

Background                The ITGB4 gene, located in region 25(17q25) of the long arm of human chromosome 17, encodes an integrin Β4 transmembrane glycoprotein, which binds to the α6 subunit to form the laminin receptor complex, which is responsible for the formation of the laminin receptor complex, through the regulation of FAK/SRC, EGFR-AKT, MEK/ERK/C-jun and other signaling pathways involved in cell adhesion, polarity maintenance and tumor biological processes. Its mutations are directly related to epidermolysis bullosa with pyloric atresia (Jeb-pa) , nonsense variants lead to lethal phenotypes, missense variants are mostly found in non-lethal types, and variant hotspots are concentrated in the FNIII and VWFA domains. In the field of tumors, ITGB4 is highly expressed in a variety of solid tumors, such as colorectal cancer, prostate cancer, non-small-cell lung carcinoma, head and neck squamous-cell carcinoma, and pancreatic ductal adenocarcinoma, it is associated with tumor progression, drug resistance (EG, EGFR-AKT pathway resistance in colorectal cancer and PD-1 inhibitor resistance in bladder cancer) and poor prognosis It affects immunotherapy response by activating the MEK/Erk/C-jun pathway to regulate PD-L1 expression, while positively correlated with NECTIN4 to enhance ADC drug sensitivity (such as enfortumab vedotin) , providing new ideas for combination therapy.

Storage                        Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw.

Formulation                Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4.

Endotoxin                   < 1 EU/mg, determined by LAL gel clotting assay 

Related products
Anti-ITGB4 mIgG2a Antibody(13H10)
Cat. No.
GM-88290AB
Size
10μg
100μg
1mg
Quote
数据展示
产品简介
Related products
数据展示
GM-88290AB
On SDS-PAGE under reducing (R)/non-reducing(N-R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of this product is more than 95% verified by SEC-HPLC.
产品简介

Species Reactivity      Human

Clone                          13H10

Source/Isotype           Mouse IgG2a,Kappa

Application                 /

Specificity                   Detects ITGB4

Gene                            ITGB4

Other Names              CD104, GP150, JEB5A, JEB5B

Gene ID                       3691 (Human)

Background                The ITGB4 gene, located in region 25(17q25) of the long arm of human chromosome 17, encodes an integrin Β4 transmembrane glycoprotein, which binds to the α6 subunit to form the laminin receptor complex, which is responsible for the formation of the laminin receptor complex, through the regulation of FAK/SRC, EGFR-AKT, MEK/ERK/C-jun and other signaling pathways involved in cell adhesion, polarity maintenance and tumor biological processes. Its mutations are directly related to epidermolysis bullosa with pyloric atresia (Jeb-pa) , nonsense variants lead to lethal phenotypes, missense variants are mostly found in non-lethal types, and variant hotspots are concentrated in the FNIII and VWFA domains. In the field of tumors, ITGB4 is highly expressed in a variety of solid tumors, such as colorectal cancer, prostate cancer, non-small-cell lung carcinoma, head and neck squamous-cell carcinoma, and pancreatic ductal adenocarcinoma, it is associated with tumor progression, drug resistance (EG, EGFR-AKT pathway resistance in colorectal cancer and PD-1 inhibitor resistance in bladder cancer) and poor prognosis It affects immunotherapy response by activating the MEK/Erk/C-jun pathway to regulate PD-L1 expression, while positively correlated with NECTIN4 to enhance ADC drug sensitivity (such as enfortumab vedotin) , providing new ideas for combination therapy.

Storage                        Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw.

Formulation                Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4.

Endotoxin                   < 1 EU/mg, determined by LAL gel clotting assay 

Related products
Message consultation
reset
submit
Message
Message consultation
reset
submit